Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

21.3%

10 terminated/withdrawn out of 47 trials

Success Rate

71.4%

-15.2% vs industry average

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

116%

29 of 25 completed trials have results

Key Signals

7 recruiting29 with results10 terminated

Enrollment Performance

Analytics

Phase 2

23(57.5%)

Phase 1

11(27.5%)

Phase 4

3(7.5%)

Phase 3

2(5.0%)

Early Phase 1

1(2.5%)

40Total

Phase 2(23)

Phase 1(11)

Phase 4(3)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (47)

Showing 20 of 47 trials

NCT06560151Phase 2Completed

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

Role: collaborator

NCT03300882Completed

PREDICT Cytomegalovirus (CMV)

Role: collaborator

NCT05997264Phase 2Completed

Anthrax AV7909 Boost Evaluation Study

Role: collaborator

NCT01278745Phase 2Terminated

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Role: collaborator

NCT01790594Phase 2Terminated

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Role: collaborator

NCT02495077Phase 2Completed

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Role: collaborator

NCT03881696Phase 3Completed

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Role: collaborator

NCT03949855Phase 2Recruiting

Belimumab With Rituximab for Primary Membranous Nephropathy

Role: collaborator

NCT07103746Phase 2Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Role: collaborator

NCT04047628Phase 3Recruiting

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Role: collaborator

NCT07015996Phase 2Recruiting

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Role: collaborator

NCT05671757Phase 1Recruiting

Daratumumab in Primary Antiphospholipid Syndrome

Role: collaborator

NCT07279467Recruiting

Study of Oral Food Challenge Biomarkers (SAFER)

Role: collaborator

NCT05285891Phase 4Active Not Recruiting

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Role: collaborator

NCT04827979Phase 1Completed

Daratumumab and Belatacept for Desensitization

Role: collaborator

NCT06504160Phase 1Recruiting

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Role: collaborator

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Role: collaborator

NCT04798079Active Not Recruiting

Systems Biology of Early Atopy

Role: collaborator

NCT03093402Phase 2Completed

JBT-101 in Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT03222492Phase 1Completed

Brentuximab Vedotin for Systemic Sclerosis

Role: collaborator